ClinicaliQ Trial Snapshot
- Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT — Recruiting • Phase III • Oncology • NCT05429632.
- What is being tested: Mocravimod, a TLR7 agonist, is being evaluated as an adjunctive and maintenance therapy in acute myeloid leukaemia (AML) patients undergoing allogeneic haematopoietic cell transplantation (allo-HCT) within a rigorous randomized controlled design.
- Patient eligibility overview: The trial enrolls AML patients deemed suitable candidates for allo-HCT who will receive mocravimod or placebo alongside standard transplantation and post-transplant protocols, with specific baseline disease and performance criteria determining participation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Eligibility Snapshot
- : * Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations * European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, [CRi] is also allowable * Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft * Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5 * Planned use of TAC-based GvHD prophylaxis * age ≥ 18 years and ≤ 75 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.